LFCR
Lifecore Biomedical, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$4.46
+0.00%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$4.39
From 52W high−49.43%
Volume269820.00
Market cap$168.82M
P/E (TTM)—
P/S (TTM)1.3x
Div yield—
Key dataSep 18, 2026
Open
$4.39
From 52W high
−49.43%
Volume
269820.00
Market cap
$168.82M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
51.9
MomentumView details →
1D Return
+0.00%
YTD Return
−45.35%
SummaryUpdated Dec 1, 2026
Lifecore Biomedical, Inc. (NASDAQ:LFCR) is a specialized pharmaceutical contract development and manufacturing organization that was originally incorporated as Landec Corporation in 1986 before changing its name in November 2022. The company went public in 1996 and is headquartered in Santa Maria, California. Lifecore operates as an integrated contract development and manufacturing organization (CDMO) with a particular focus on hyaluronic acid-based pharmaceutical products and aseptic fill-finish services for injectable medications.
Similar companies
Latest newsMore news →
LifeCore Biomedical, Inc. reported its Q2 2026 financial results with total revenue of $34.2 million, a net loss of $6.2 million, and diluted EPS of -$0.19.47d agoLifecore Biomedical signed three new customer agreements, including a technology transfer agreement for a regenerative medicine late-stage development program and two additional agreements supporting early-stage programs for a global medical technology company.54d agoLifecore Biomedical signed a new agreement with a global pharmaceutical company to perform technical transfer services for commercial manufacturing of an injectable neurology product.97d ago